Accession Number:

ADA355333

Title:

Characterization of a Novel Pl85erbB2/neu Ligand from Breast Cancer Cells.

Descriptive Note:

Final rept. 1 Jul 96-30 Jun 98

Corporate Author:

BETH ISRAEL DEACONESS MEDICAL CENTER BOSTON MA

Personal Author(s):

Report Date:

1998-08-01

Pagination or Media Count:

26.0

Abstract:

Ascites 13762 cells, a highly metastatic and malignant rat mammary adenocarcinoma cell line, express a cell surface glycoprotein called ASGP2 that possesses an epidermal growth factor BGF-like domain believed to interact with and stimulate growth factor receptors of the ErbB family. These cells also express ErbB2, a member of the ErbB family whose aberrant activation probably plays a role in tumoigenesis and tumor progression in a significant subset of breast cancer patients. ASGP2 and ErbB2 exist in a complex at the surface of ascites 13762 cells, raising the possibility that these cells stimulate their own growth or malignancy through an autocrine mechanism involving the ASGP2ErbB2 interaction. The overall goal of the studies outlined in this proposal was to test this hypothesis. Studies were aimed at examining the effect of ASGP2ErbB2 complex expression on the growth and transformation of cultured tumor cells. We expressed ASGP2 in an ErbB2-expressing human melanoma cell line under an inducible promoter. We observed that the result of the interaction of the ASGP2 with the ErbB2 receptor is to potentiate the response of that receptor to BGF-like growth factors, both in receptor tyrosine phosphorylation and in the progression of the cells through the cell cycle.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE